- Report
- February 2025
- 110 Pages
Global
From €5257EUR$5,950USD£4,584GBP
- Report
- September 2025
- 147 Pages
Global
From €3533EUR$3,999USD£3,081GBP
- Report
- September 2025
- 142 Pages
Global
From €3533EUR$3,999USD£3,081GBP
- Report
- August 2025
- 149 Pages
Global
From €3533EUR$3,999USD£3,081GBP
- Report
- May 2025
- 140 Pages
Global
From €3533EUR$3,999USD£3,081GBP
- Report
- May 2025
- 219 Pages
Global
From €2209EUR$2,500USD£1,926GBP
- Report
- April 2025
- 182 Pages
Global
From €3976EUR$4,500USD£3,467GBP
- Report
- March 2025
- 183 Pages
Global
From €3976EUR$4,500USD£3,467GBP
- Report
- January 2026
- 194 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 182 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 180 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 187 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 180 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 193 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 183 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 195 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 193 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 183 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 185 Pages
Global
From €3480EUR$3,939USD£3,035GBP
- Report
- January 2026
- 187 Pages
Global
From €3480EUR$3,939USD£3,035GBP

The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more